Roche's stock is perceived as undervalued amidst its pipeline advancements.
Roche (SWX:ROP) is seen as undervalued despite its significant progress in developing new therapies. The stock closed at US$358.57, down 1.02% for the day, and has decreased by 16.86% year-to-date.
Investor takeaway: Investors may want to keep an eye on Roche's current valuation and ongoing advancements.
Advertisement
Roper Technologies Inc
ROP.US
ROP.US
Roper Technologies Inc
WealthAwesomeMarket cap
$35.46B
P/E
15.1x
Div. yield
0.98%
Div. / share
$3.56
52W high
$514.14
52W low
$304.43
1W change
+0.71%
Beta
0.75
Analyst Price Targets
Based on 19 analysts covering ROP · as of Oct 5, 2026
Wall Street analysts forecast ROP stock price to rise 20.6% over the next 12 months.
Consensus
Buy3.58 / 5.00
Avg. Target
C$439.43
+20.6% Upside
Current Price
C$364.23
Last close
Analyst Breakdown (19 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ROP's historical volatility
30-Day Vol
26.8%
Annualized
90-Day Vol
31.0%
Annualized
Trend (90d)
+19.6%
Annualized drift
90d Mean
C$390.62
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$372.82 | C$339.85 – C$408.99 |
| 60 trading days | C$381.62 | C$334.78 – C$435.01 |
| 90 trading days | C$390.62 | C$332.74 – C$458.57 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Roche's stock closed at US$358.57, down 1.02% on the day.
The stock is currently trading below its 50-day moving average of US$390.53, suggesting it may be undervalued.
Bull case
Recent advancements in Roche's pipeline could lead to future revenue growth and a better market perception.
Bear case
Concerns about Roche's valuation might continue if its pipeline developments do not result in successful product launches.
Roche's Stock Valuation Under Scrutiny
Advertisement
Roche's stock is considered undervalued following a recent analysis. It closed at US$358.57, reflecting a 1.02% decline in the last trading session. However, it gained 2.88% over the past week, though it is still down 11.74% for the month. The current price is significantly below its 50-day moving average of US$390.53 and its 200-day moving average of US$368.30, indicating a potential buying opportunity for some investors.
Current Stock Performance Metrics
Roche's trading volume was 458,516 shares, which is only 0.51 times the 20-day average volume of 900,420 shares. This relatively low volume may suggest decreased trading interest among investors. Over the past year, the stock has traded within a 52-week range of US$304.43 to US$515.88, currently sitting at about 26% of that range. The company's P/E ratio is 15.095, and its market capitalization is approximately US$35.83 billion, indicating a solid profit margin of 30.2%.
Future Developments to Monitor
Moving forward, investors should closely watch Roche's pipeline developments, as they could impact the company's market valuation. The average analyst target for Roche is currently US$439.43, suggesting an upside potential of about 22.6% from the current price. As the company continues to advance its therapies, the market's response will be crucial in determining if the stock's current valuation adjusts to reflect its growth potential.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
